Progenics Pharmaceuticals Inc

Progenics Pharmaceuticals — Proxy Contest (October 2019)

162 slides from Progenics Pharmaceuticals's proxy contest presentation, Oct 21, 2019

  1. Slide 1: Board Reconstitution is Necessary to Save Progenics Pharmaceuticals, Inc.

    OCTOBER 2019 Board Reconstitution is Necessary to Save Progenics Pharmaceuticals, Inc. Velan Velan Capital, Capital, L.P.L.P. – ALL – ALL RIGHTS RIGHTS RESERVED RESERVED 1

  2. Slide 2: Disclosure & Disclaimer

    Disclosure & Disclaimer THIS PRESENTATION IS FOR DISCUSSION AND GENERAL INFORMATIONAL PURPOSES ONLY. IT DOES NOT HAVE REGARD TO THE SPECIFIC INVESTMENT OBJECTIVE, FINANCIAL SITUATION, SUITABILITY, OR THE PARTICULAR NEED OF ANY SPECIFIC PERSON WHO MAY RECEIVE THIS PRESENTATION, AND SHOULD NOT BE TAKE

  3. Slide 3: Table of Contents

    Table of Contents Executive Summary 4 Performance, Stockholder & Governance Issues • Dismal Share Price Performance 40 • Entrenchment-Minded Tactics & Egregious Governance Practices 43 • Attempt to Avoid Accountability – Agreeing to a Poor Deal with Lantheus 50 • Ineffective Oversight of Underqualif

  4. Slide 4: Executive Summary

    Executive Summary Velan Capital, L.P. – ALL RIGHTS RESERVED 4

  5. Slide 5: Introduction to Velan Capital

    Introduction to Velan Capital Velan Capital, L.P. (“Velan Capital”) is a private investment partnership that strives to optimize long-term value creation All of its capital comes from its principals (not passive investors) We are truly long-term owners and not agents Focus on undervalued healthcare

  6. Slide 6: Situation Overview

    Situation Overview Velan Capital, including the other participants in its call for change (“Velan”, “Velan Group”, or “we”), collectively own 11.7% of the outstanding shares of Progenics Pharmaceuticals, Inc. (“PGNX”, “Progenics”, or the “Company”), representing an increased position since the Compa

  7. Slide 7: Velan's Rationale for Change

    Velan’s Rationale for Change PERFORMANCE, STOCKHOLDER & OPERATIONAL GOVERNANCE ISSUES CONCERNS DISMAL BOTCHED SHARE PRICE COMMERCIAL PERFORMANCE EXECUTION ENTRENCHMENT TACTICS MANUFACTURING & EGREGIOUS & SUPPLY CHAIN GOVERNANCE PRACTICES ISSUES INEFFECTIVE OVERSIGHT QUESTIONABLE OF UNDERQUALIFIED CL

  8. Slide 8: Dismal Company Stock Performance

    Dismal Company Stock Performance Stock Price (as of 10/1/2019) $4.95 Market Cap ($M) ~$430M PGNX TSR over CEO tenure -18.85% Peer(1) TSR over CEO tenure 33.89% (1 YR) Total Shareholder Return (3 YR) Total Shareholder Return (5 YR) Total Shareholder Return 78.85% 48.88% 9.10% 1.63% (0.80%) (1.60%) Pr

  9. Slide 9: A Board in Need of Refreshment

    A Board in Need of Refreshment Board in need of fresh perspectives, more relevant experience, better track records and stockholder alignment Targeted Directors Baker (CEO), Scheinberg and Williams all have tenures of 10+ years Dr. Scheinberg has been a member of the Board since 1996 Our 2019 Annual

  10. Slide 10: Missed Opportunities

    Missed Opportunities 1095 1095 is a radiopharmaceutical that binds to prostate cancer cells to deliver highly targeted radiation 1095 was acquired in January 2013 with strong clinical data already in hand 1095 laid dormant and remained undeveloped by Progenics until the license of a competing produc

  11. Slide 11: Potential Alarming Issues

    Potential Alarming Issues POTENTIAL SUPPLY CHAIN CONCERNS(1) Upcoming IRE transition period may require plant shutdown (sole iodine-131 supplier, which is the radioactive payload for AZEDRA and 1095) – need for additional backup suppliers Centre for Probe Development & Commercialization (“CPDC”) imp

  12. Slide 12: Lack of Concessions in Prior Campaign

    Lack of Concessions in Prior Campaign Velan's Initial Velan's Latest Settlement Offer Settlement Offer (as of June 28, 2019) Velan's Add 3 Directors from Accepted Company's Offer to Add 2 Latest Velan Directors with No ESG Concerns and Settlement No Ties to Velan Offer Requested Two Non-Voting Board

  13. Slide 13: Lack of Concessions in Prior Campaign (Contd)

    Lack of Concessions in Prior Campaign (Cont’d) First Offer: Press Release, June 19, 2019 Second Offer: Press Release, June 27, 2019 Velan made substantially more concessions than the Board in its negotiations leading up to the 2019 Annual Meeting Source: Press releases. Velan Capital, L.P. – ALL RIG

  14. Slide 14: Engagement Since 2019 Annual Meeting

    Engagement Since 2019 Annual Meeting Date Key Events Leading up to Consent Solicitation July 11, 2019 Velan publicly stated its desire to negotiate with Progenics and move to a settlement. Velan team members even stayed in (Annual Meeting) New York City after the Annual Meeting and sought to meet wi

  15. Slide 15: Poor Governance Continues Despite Stockholder Vote at 2019 Annual Meeting

    Poor Governance Continues Despite Stockholder Vote at 2019 Annual Meeting Continued Failure to Listen to Stockholder Voices Despite the overwhelming vote against the re-election of Messrs. Crowley and Kishbauch at the July 11, 2019 Annual Meeting, the Company chose to delay their resignations until

  16. Slide 16: A Suspect Transaction

    A Suspect Transaction On October 2, 2019, Lantheus Holdings, Inc. (NASDAQ: LNTH) announced an all-stock merger with Progenics In Velan’s view, the Board abandoned its fiduciary duties by choosing to sell Progenics at a massive discount in an attempt to prevent the voices of stockholders from being h

  17. Slide 17: A Suspect Transaction (Contd)

    A Suspect Transaction (Cont’d) After the transaction was announced, we pressed CEO Baker on the timing of the deal and whether a process was run • CEO Baker stated that Progenics “had a transaction that was doable” and argued for the transaction by saying its “not like [Progenics stockholders] are g

  18. Slide 18: Opinion of Governance Experts

    Opinion of Governance Experts One corporate governance expert said the decision for two outgoing directors to vote on such a serious matter is concerning. “It was legal but that doesn’t make it the correct approach. I would consider it bad form,” said Professor Charles Elson, Director of the John L.

  19. Slide 19: Lantheus Proposal Does Not Add Up

    Lantheus Proposal Does Not Add Up Lantheus is getting Progenics’ entire product portfolio for FREE at the current implied offer price of $4.78 per share as of October 15, 2019 (based on Lantheus stock price of $19.11 multiplied by 0.2502 exchange ratio) The value of RELISTOR royalties are $170mm per

  20. Slide 20: Company's Perspectives in June

    Company’s Perspectives in June The images below are from the Company’s June 2019 investor presentation – $300+ million peak net sales from AZEDRA and RELISTOR alone with material upside when PyL launches in $500 million market (1095 is excluded from this analysis but, in Velan’s view, represents a s

  21. Slide 21: Company's Perspectives in June (Contd)

    Company’s Perspectives in June (Cont’d) The image below is excerpted from the Company’s presentation to proxy advisory firms in June 2019 Progenics referenced analyst price targets and ratings as justification for why change was not necessary Days before this presentation, the Company also stated it

  22. Slide 22: Lantheus Lacks the Skills to Save Progenics

    Lantheus Lacks the Skills to Save Progenics Progenics is facing three key operational issues – we don’t believe Lantheus can solve these issues given their own similar problems, as outlined below, and their lack of experience with radiotherapeutics PGNX Relevant Velan Nominee Lantheus’ Own Issues Is

  23. Slide 23: We Believe We Have a Better Plan and Can Save Progenics With New Directors

    WE BELIEVE WE HAVE A BETTER PLAN AND CAN SAVE PROGENICS WITH NEW DIRECTORS AND LEADERSHIP Let’s Explore Velan Capital, L.P. – ALL RIGHTS RESERVED 23

  24. Slide 24: A Reconstituted Board

    A Reconstituted Board Our Nominees would bring complementary skill sets to the remaining directors – Mr. Campbell and Dr. Ferrante – and would more than replace the skillsets of the three targeted directors Replacing CEO Mark Baker with three Nominees with ~75 years in collective pharma experience (

  25. Slide 25: Highly-Qualified, Independent Nominees

    Highly-Qualified, Independent Nominees Previously Co-Founder and COO of Previously CFO and General Advanced Accelerator Counsel of AAA, and led the Applications (“AAA”), building the diligence and negotiations in its business from scratch and selling sale to Novartis for $3.9 billion to Novartis for

  26. Slide 26: Our Nominees Bring Diverse Skill Sets

    Our Nominees Bring Diverse Skill Sets Our Nominees would bring a wide array of skillsets to the Progenics Board from radiopharmaceutical experience to governance expertise and are fully independent of Velan and Progenics Our Nominees would not just replace the targeted directors – we believe they wi

  27. Slide 27: Approach to Improving Progenics

    Note to Readers, a Approach to Improving Progenics Green Border Means Page Contains Plan / Actions for Nominees ACTIONS WITHIN FIRST 100 DAYS PLAN BEYOND 100 DAYS REFINE & IDENTIFY ROADMAP EXECUTE & PLAN FOR LONG-TERM Ensure successful transition from interim to full-time CEO Commence search for top

  28. Slide 28: Implementation of 100-Day Plan

    Implementation of 100-Day Plan Our Nominees will immediately engage a search firm to select a new top-tier CEO, ideally within the first two months, while simultaneously evaluating the broader leadership team and assessing internal opportunities Ensuring the appropriate management and employees are

  29. Slide 29: Summary of 100-Day Plan & Action Items

    Summary of 100-Day Plan & Action Items Our Nominees are well-versed in the current issues facing Progenics and have a concrete plan to save Progenics Functional Where Our Nominees Current Issues Select Key Action Items Area Would Focus CEO has no pharmaceutical Identification of new top-tier CEO Nom

  30. Slide 30: Identification of Full-Time CEO

    Identification of Full-Time CEO In the first 60 days, the Board’s focus would be selecting a new CEO and evaluating the other members of the current leadership team while assessing internal candidates Progenics management and employees are vital and the reconstituted Board intends to work collaborat

  31. Slide 31: Key Employee Retention Plan

    Key Employee Retention Plan A key component of working collaboratively and ensuring continuity is a key employee retention plan Progenics management and employees are vital and our Nominees plan on working collaboratively to build a highly capable team to improve the culture and drive / ability to t

  32. Slide 32: Plan: Accountability & Incentives

    Plan: Accountability & Incentives Our Nominees intend to make the following improvements at Progenics, if elected, to enhance governance, adjust compensation (to align with stockholders and tie directly to goals) and provide management oversight CEO and management team Board to engage search firm to

  33. Slide 33: Plan: Reinvigorating AZEDRA's Launch

    Plan: Reinvigorating AZEDRA’s Launch For AZEDRA’s commercial success, two critical components need to be assessed 1 Ensuring Patient access for identified patients (including those waiting to be scheduled and those to be scheduled in the future) – the key to reinvigorating AZEDRA’s launch Our Nomine

  34. Slide 34: Plan: Partnering PyL

    Plan: Partnering PyL PyL is an attractive diagnostic imaging radiopharmaceutical that is currently in a Phase 3 clinical trial PyL’s half life is two hours meaning that logistics and supply chain coordination are critical Our Nominees believe Progenics should partner or co-promote PyL with a commerc

  35. Slide 35: Plan: Operations Success / Product Access

    Plan: Operations Success / Product Access Perform root cause analysis and implement CAPA to define the supply chain issues (and order of magnitude) and the timeline for resolution as well as any regulatory requirements Increase reliability and trust between patients and physicians How much product c

  36. Slide 36: Plan: Clinical Development Progress

    Plan: Clinical Development Progress Our Nominees intend to engage with Progenics’ clinical team and the FDA to understand regulatory feedback and potential path forward in order to shorten time to market and maximize commercial potential while meeting unmet needs of cancer patients Need to review FD

  37. Slide 37: Plan: Improving Financial Picture

    Plan: Improving Financial Picture Evaluate current Progenics employees and organizational structure Determine whether best to have functions in-house vs. outsourced (e.g., clinical / R&D functions done by clinical research organization) Reduce administrative burden PAGE CONTAINS NOMINEE PLAN / ACTIO

  38. Slide 38: Our View on Progenics Potential Value

    Our View on Progenics’ Potential Value Includes 50% of NOLs prior to 2018; includes D&A and $65 million in CapEx Represents estimate as of YE2019 ($25mm quarterly cash burn, RELISTOR milestone payment and debt paydown) Unaffected Price: $4.95 Source: SEC filings. Note: Assumes 12% discount rate and

  39. Slide 39: Vote the GREEN Consent Card

    Vote the GREEN Consent Card To Fight Dismal stock price performance Unnecessary dilution without stockholder representation Lack of proper Board oversight, including the appointment and tolerance of an underqualified management team Operational blunders + minimal progress Lack of transparency / disc

  40. Slide 40: Dismal Share Price Performance

    Performance, Stockholder & Governance Issues Dismal Share Price Performance Velan Capital, L.P. – ALL RIGHTS RESERVED 40

  41. Slide 41: Stock Price Reflects Poor Execution

    Stock Price Reflects Poor Execution PGNX has underperformed on both an absolute and relative basis over almost any time period Since 1996: Dr. Scheinberg joined the Board Since 2007: Ms. Williams joined the Board Since 2009: Mr. Baker joined the Board In more recent years while AZEDRA approval and l

  42. Slide 42: Exodus of Investors and Analysts

    Exodus of Investors and Analysts Over the past five years, Progenics has had numerous notable healthcare investors exit their position 2015: Lord Abbett and Tiger Management 2016: Highbridge Capital 2017: Broadfin Capital and Wellington Management 2018: Baker Brothers, Fidelity Management & Research

  43. Slide 43: Entrenchment-Minded Tactics & Egregious Governance Practices

    Performance, Stockholder & Governance Issues Entrenchment-Minded Tactics & Egregious Governance Practices Velan Capital, L.P. – ALL RIGHTS RESERVED 43

  44. Slide 44: Board Stock Ownership

    Board Stock Ownership The Progenics Board has minimal ownership and alignment with stockholders Collectively, all directors own 284,322 shares of common stock, excluding shares underlying exercisable options Represents 0.3% of shares outstanding Collectively, all non-executive directors own 123,182

  45. Slide 45: Scheinberg's Conflicts & Prior Board Roles

    Scheinberg’s Conflicts & Prior Board Roles Dr. Scheinberg was compensated $237,159 in 2018 for his service as a Progenics director Memorial Sloan Kettering has had recent issues regarding its employees and outside financial interests Sloan Kettering has identified a potential conflict as “serving on

  46. Slide 46: Board Has Its Own Blemishes

    Board Has Its Own Blemishes The Board has frequently commented on Velan’s prior price increases but has failed to look in the mirror at its own ESG issues Previously disclosed issues with Mr. Crowley (SEC order and a subsequent fine) and Mr. Kishbauch (OraPharma securities fraud settlement) Mr. Bake

  47. Slide 47: Velan's Outreach to Progenics Repeatedly Dismissed

    Velan’s Outreach to Progenics Repeatedly Dismissed In 2018 and early 2019, Velan reached out to Progenics management on multiple occasions After a telephonic meeting in November 2018 and an in-person meeting in January 2019, the Company went silent despite Velan’s continued outreach In February and

  48. Slide 48: Engagement Since 2019 Annual Meeting

    Engagement Since 2019 Annual Meeting Date Key Events Leading up to Consent Solicitation July 11, 2019 Velan publicly stated its desire to negotiate with Progenics and move to a settlement. Velan team members even stayed in (Annual Meeting) New York City after the Annual Meeting and sought to meet wi

  49. Slide 49: Poor Governance Continues Despite Stockholder Vote at 2019 Annual Meeting

    Poor Governance Continues Despite Stockholder Vote at 2019 Annual Meeting Continued Failure to Listen to Stockholder Voices Despite the overwhelming vote against the re-election of Messrs. Crowley and Kishbauch at the July 11, 2019 Annual Meeting, the Company chose to delay their resignations until

  50. Slide 50: Attempt to Avoid Accountability – Agreeing to a Poor Deal with Lantheus

    Performance, Stockholder & Governance Issues Attempt to Avoid Accountability – Agreeing to a Poor Deal with Lantheus Velan Capital, L.P. – ALL RIGHTS RESERVED 50

  51. Slide 51: Current Transaction Not in Best Interests

    Current Transaction Not in Best Interests 1 Price is not reflective of Progenics’ potential and subjects stockholders to new risks via Lantheus’ stock The closing stock prices on the day of the transaction implied a $4.76 per share value for Progenics Progenics’ stock closed at $5.50, implying stock

  52. Slide 52: Transaction Valuation & Consideration

    1 Transaction Valuation & Consideration There are multiple ways to evaluate this transaction and safely determine that Progenics was undervalued A Stock price reactions Progenics has traded above the implied price of the deal signaling dislike of the current deal Transaction price is at a significan

  53. Slide 53: Lantheus Stock May Be Overvalued

    1 Lantheus Stock May Be Overvalued We see the benefits for why Lantheus would like to utilize its stock and preserve cash (and debt capacity) Unfortunately, this means that Progenics’ stockholders need to assess the value and risk of Lantheus One quick sanity check is to see how management treats it

  54. Slide 54: Transaction Timing & Fiduciary Duties

    2 Transaction Timing & Fiduciary Duties The timing of this transaction is suspect in Velan’s view On October 4, 2019, we spoke with CEO Baker regarding his thoughts on the transaction CEO Baker stated that Progenics “had a transaction that was doable” and argued for the transaction by saying its “no

  55. Slide 55: Termination Fee: A Parting Gift

    2 Termination Fee: A Parting Gift The Board agreed to an $18 million termination fee with Lantheus – which we view as a thinly veiled threat to stockholders that if they vote out the current Board, the Company could be negatively impacted Rather than allowing stockholders to decide on the future of

  56. Slide 56: Board Further Avoiding Accountability

    2 Board Further Avoiding Accountability The Board amended the Progenics’ By-laws (the “Bylaw Amendment”) on October 1, 2019, the same day it entered into the Lantheus transaction, to add an exclusive venue provision, which is widely viewed as stockholder-unfriendly We believe the Board adopted the B

  57. Slide 57: Lantheus Lacks the Skills to Save Progenics

    3 Lantheus Lacks the Skills to Save Progenics Progenics is facing three key operational issues – we don’t believe Lantheus can solve these issues given their own similar problems, as outlined below, and their lack of experience with radiotherapeutics PGNX Relevant Velan Nominee Lantheus’ Own Issues

  58. Slide 58: Ineffective Oversight of Underqualified & Overpaid Management

    Performance, Stockholder & Governance Issues Ineffective Oversight of Underqualified & Overpaid Management Velan Capital, L.P. – ALL RIGHTS RESERVED 58

  59. Slide 59: Ineffective Oversight of Unqualified Team

    Ineffective Oversight of Unqualified Team Mark Baker’s biography “Mr. Baker, 64, Chief Executive Officer (“CEO”), joined us in 2005 as Senior Vice President & General Counsel and Secretary. In 2008, he was appointed Executive Vice President, Corporate, in 2009 became President and a director, and ha

  60. Slide 60: Rewarding Perpetual Underperformance

    Rewarding Perpetual Underperformance Board’s Assessment of Performance Recent Events Performance Goals in Velan’s Commentary Metric 2017 & 2018 AZEDRA is a highly valuable asset with AZEDRA PDUFA extended and potential to fill an unmet need for cancer subsequently approved in July 2018 patients Firs

  61. Slide 61: Misaligned Compensation Program

    Misaligned Compensation Program The Board has approved outsized pay while value has been destroyed, which we believe represents a clear misalignment of interests with stockholders Annual incentives are 100% discretionary Long-term incentives are 0% performance-based The Compensation Committee has ap

  62. Slide 62: Annual Incentives are 100% Discretionary

    Annual Incentives are 100% Discretionary The annual bonus is based on four metrics that are vague and entirely discretionary Each of the four targets required qualification from the Compensation Committee to justify payouts Even with the exclusion of an impairment charge related to failure of the 14

  63. Slide 63: Long-Term Incentives: 0% Performance-Based

    Long-Term Incentives: 0% Performance-Based The Progenics Compensation Committee grants long-term incentive awards exclusively in the form of stock options without any performance-based conditions Most shareholders, and leading proxy advisers ISS and Glass Lewis, don’t consider options to be performa

  64. Slide 64: Lack of Transparency & Misleading Statements

    Performance, Stockholder & Governance Issues Lack of Transparency & Misleading Statements Velan Capital, L.P. – ALL RIGHTS RESERVED 64

  65. Slide 65: Board's Habit of Misleading Stockholders

    Board’s Habit of Misleading Stockholders Ask yourself: why is the Company and the Board more focused on disparaging one of its largest stockholders than they are on explaining how they plan to cure the prolonged period of pain experienced by stockholders? Given the latest announcement to sell the Co

  66. Slide 66: Lack of Regulatory Clarity

    Lack of Regulatory Clarity Progenics has not been forthright with investors regarding the interactions with (and potential feedback from) the FDA on its Phase 2 clinical trial Progenics announced its decision to move 1095 into Phase 2 trial in October 2018 Progress is needed but why make the decisio

  67. Slide 67: AZEDRA's Manufacturing Mystery

    AZEDRA’s Manufacturing Mystery AZEDRA’s manufacturing situation appears fine per the risk disclosures in the Company’s 2018 10-K but physician feedback and two recent developments raise serious related concerns Manufacturing facility acquisition in February 2019 for $8 million Manufacturing agreemen

  68. Slide 68: Timeline of Manufacturing Events

    Timeline of Manufacturing Events See below for a timeline of public events and disclosure regarding AZEDRA’s manufacturing. There are a few concerning factors to Velan: Progenics raised $75 million in capital after one of its suppliers received an FDA import ban The Company stated they needed to mak

  69. Slide 69: Learnings Likely Confirm Our Suspicions

    Learnings Likely Confirm Our Suspicions AZEDRA issues POTENTIAL AZEDRA ISSUES(1) Backup supply Progenics only has one production line when it is common for radiopharmaceutical companies to have multiple lines to ensure supply. Multiple lines are necessary in case the Company needs to do validation o

  70. Slide 70: Import Ban: To Disclose or Not to Disclose?

    Import Ban: To Disclose or Not to Disclose? CPDC was placed on FDA import ban on August 1, 2019 which has not been disclosed by Progenics to-date even though CPDC was the manufacturer for AZEDRA and currently manufactures 1095 A similar company, Cellectar Biosciences, also had a radiopharmaceutical

  71. Slide 71: Potentially Misleading Public Statement

    Potentially Misleading Public Statement In June 2019, during the 2019 Annual Meeting campaign, the Company published a press release noting its first 1095 patient was dosed We subsequently were told that at the time of the press release, the patient was in fact not yet dosed with 1095 but had been d

  72. Slide 72: Ruling with an Iron Fist

    Ruling with an Iron Fist There appear to be multiple concerning issues regarding lack of disclosure and misleading statements If this is true, why wouldn’t an employee step forward to say something? We believe employees are hesitant to speak out to change the narrative at Progenics In Velan’s opinio

  73. Slide 73: Velan's Attempt to Confirm These Issues

    Velan’s Attempt to Confirm These Issues On September 23, 2019, Velan submitted a books and records request to Progenics, which Velan supplemented on October 2, 2019, after more concerning issues came to light to investigate potential wrongdoing, mismanagement and / or breaches of fiduciary duties Th

  74. Slide 74: Botched Commercial Execution

    Operational Concerns Botched Commercial Execution Velan Capital, L.P. – ALL RIGHTS RESERVED 74

  75. Slide 75: Prior Communication to Stockholders

    Prior Communication to Stockholders From AZEDRA’s approval in July 2018 through the first patient dosing in June 2019, the Company stated that the patient dosings would take “weeks” and were “pleased with the progress” when in fact it took MORE THAN TEN MONTHS to dose a single patient FDA APPROVAL P

  76. Slide 76: Overpromised and Underdelivered

    Overpromised and Underdelivered In July 2018, Progenics stated: AZEDRA was “ready for commercialization” Reimbursement should be a “smoother, quicker process” for centers that participated in the trial Patient identification and dosing should take “eight weeks” Nuclear process should take a “matter

  77. Slide 77: No Visibility to Improving the Launch

    No Visibility to Improving the Launch In its Q2 2019 earnings release, the Company highlighted the “challenging” commercial launch for AZEDRA This represents a stark change of tone from the message during the 2019 Annual Meeting campaign where the Board and management had apparently “mastered” AZEDR

  78. Slide 78: AZEDRA: Comparison to Similar Products

    AZEDRA: Comparison to Similar Products Progenics received approval for AZEDRA in July 2018 and dosed its first patient in June 2019 We could not find ONE other launch that took more than TEN MONTHS to dose a patient With no Orange Book patents, each day AZEDRA was delayed was a day lost of its FDA o

  79. Slide 79: Manufacturing & Supply Chain Issues

    Operational Concerns Manufacturing & Supply Chain Issues Velan Capital, L.P. – ALL RIGHTS RESERVED 79

  80. Slide 80: Potential Supply Chain Issues & Concerns

    Potential Supply Chain Issues & Concerns Upcoming IRE plant transition and potential shutdown (sole I-131 supplier)(1) – need for backup suppliers CPDC import ban(2) Capacity and production limitations for 1095 (at CPDC) and AZEDRA (in Somerset)(3) Uncertain PyL supply chain (which is critical given

  81. Slide 81: Somerset Facility & Capacity Concerns

    Somerset Facility & Capacity Concerns Somerset “facility” currently is constituted of one manufacturing suite with one manufacturing line in an old IBA / Zevacor facility Progenics paid $8 million for this facility, which based on experts we’ve spoken with suggests they vastly overpaid As a referenc

  82. Slide 82: Operating Without a Backup Supplier

    Operating Without a Backup Supplier The Company’s sole supplier of iodine-131 (I-131), IRE located in Belgium, has an upcoming plant transition planned to switch to low-enriched uranium The American Medical Isotopes Production Act of 2012 (AMIPA) prevents the U.S. Nuclear Regulatory Commission (NRC)

  83. Slide 83: Questionable Clinical Program Decision Making

    Operational Concerns Questionable Clinical Program Decision Making Velan Capital, L.P. – ALL RIGHTS RESERVED 83

  84. Slide 84: AZEDRA: Advanced at Glacial Pace

    AZEDRA: Advanced at Glacial Pace Progenics acquired AZEDRA from MIP in January 2013 In November 2013, Progenics announced it was “relaunching the registrational trial” In January 2015, Progenics noted that it had dosed the first subject since trial was resumed Similar to its commercial struggles, it

  85. Slide 85: 1095: Blind But Now I See

    1095: Blind But Now I See In the six years since acquiring 1095, arguably its most valuable asset, we believe the Board has shown continual neglect and a lack of urgency STANDING STILL AND WATCHING THE COMPETITION PASS BY It appears to have taken the foresight of Endocyte and its acquisition by Nova

  86. Slide 86: Inefficient Financial Management

    Operational Concerns Inefficient Financial Management Velan Capital, L.P. – ALL RIGHTS RESERVED 86

  87. Slide 87: Progenics Cash Burn is Out of Control

    Progenics’ Cash Burn is Out of Control In 2018, the Board considered the financial corporate goal to be “substantially met” while reporting SG&A and development expenses, excluding one-time write-offs, north of $60 million (which exceeded its undemanding internal budget); the Company cannot even mai

  88. Slide 88: Expensive and Costly Corporate HQ

    Expensive and Costly Corporate HQ Progenics’ headquarters is in One World Trade Center 26,000 square feet under lease agreement expiring in September 2030 Progenics was previously headquartered in Tarrytown, NY but relocated to NYC in 2016 We heard it was to be near CEO Baker’s Brooklyn residence In

  89. Slide 89: Persistent & Unnecessary Dilution

    Persistent & Unnecessary Dilution Since Mr. Crowley and CEO Baker joined the Board in 2009, Progenics has completed equity financings raising more than $200 million, which currently represents over 50% of the Company’s fully-diluted equity value In 2018 alone, ~$100 million of dilutive equity was ra

  90. Slide 90: Illustrating Propensity for Dilution

    Illustrating Propensity for Dilution The Progenics Board since 2009, while CEO Baker, Dr. Scheinberg and Ms. Williams have served as directors, has overseen persistent and unnecessary dilution Investors continue to be diluted while the Company’s stock price continues to languish Today’s share count

  91. Slide 91: Ensuring Future Commercial Success

    100-Day Plan Ensuring Future Commercial Success Velan Capital, L.P. – ALL RIGHTS RESERVED 91

  92. Slide 92: Ensuring AZEDRA's Commercial Success

    Ensuring AZEDRA’s Commercial Success A key focus of the Board will be identifying the issues that have plagued AZEDRA’s lackluster launch and engage in a multi-pronged approach to ensure its commercial success Multiple Nominees have extensive experience in pharmaceuticals and radiopharmaceuticals Dr

  93. Slide 93: AZEDRA: A Rare Opportunity

    AZEDRA: A Rare Opportunity There are multiple complexities with launching a pharmaceutical product but three issues come to the forefront on AZEDRA given it is for an orphan patient population with a potential patient population of <1,000 patients Logistics and supply chain for radiopharmaceutical w

  94. Slide 94: Potential Operational Delays & Issues

    Potential Operational Delays & Issues Velan believes an undisclosed reason has caused the ten-month delay from approval to (its botched and limited) launch – manufacturing issues In March 2018, the Company’s 2017 10-K stated that Progenics is “in the final stages of establishing manufacturing capaci

  95. Slide 95: Reinvigorating AZEDRA's Launch

    Reinvigorating AZEDRA’s Launch Our Nominees believe AZEDRA needs to be reinvigorated and almost treated as a “re- launch” of a rare orphan drug Our Nominees would take the following steps: Re-engage physicians and key centers of excellence PAGE CONTAINS NOMINEE PLAN / ACTIONS Establish relationships

  96. Slide 96: Working with Centers of Excellence

    Working with Centers of Excellence With only 25-30 key targeted centers, Progenics and their employees should have active, frequent dialogue with these centers regarding AZEDRA’s commercial launch Based on our research, multiple key centers (that dose large number of patients) are still not online I

  97. Slide 97: Patient Advocacy & Awareness

    Patient Advocacy & Awareness AZEDRA is the first approved treatment for MIBG-avid malignant, recurrent, and / or unresectable pheochromocytoma and paraganglioma (“PheoPara”) PheoPara are rare cancers with an annual incidence of 2 to 8 per million in the U.S. Implies ~500 to ~2,500 patients based on

  98. Slide 98: Meeting Patient Needs

    Meeting Patient Needs AZEDRA is only available at a few key centers in the U.S. (13 active centers as of August 2019) and costs ~$150,000 for a 500 mCi dose In addition to awareness, Progenics needs to collaborate with patients to make sure they are taken care of during their time of need PAGE CONTA

  99. Slide 99: Payor and Hospital P&T Engagement

    Payor and Hospital P&T Engagement A key component of patient access is ensuring payors and hospital pharmacy and therapeutics (“P&T”) committees are educated on AZEDRA’s value proposition and are financially incentivized to approve payment Payors understand orphan drug dynamics and pricing necessary

  100. Slide 100: Metrics for Stockholder Communication

    Metrics for Stockholder Communication A successful pharmaceutical product launch can be intuitive but often a company’s ability to set and define metrics that are quantifiable and communicable allow a board and stockholders to properly assess performance Throughout 2019, Progenics continues to refer

  101. Slide 101: Ensuring Patient Access Today

    Ensuring Patient Access Today Our Nominees intend to determine if the access issue is due to team issues CEO Mark Baker has no prior pharmaceutical experience SVP, Commercial Bryce Tenbarge was previously commercial lead for a pre-revenue company Hiring of Huw Jones as VP, Commercial in July appears

  102. Slide 102: Future New Patient Identification

    Future New Patient Identification Once AZEDRA’s access issues are resolved, in order to ensure new patients are identified, our Nominees intend to take several steps PHYSICIAN EDUCATION Physician education is necessary for orphan products PAGE CONTAINS NOMINEE PLAN / ACTIONS When educated, physician

  103. Slide 103: Instilling Operational Experts

    100-Day Plan Instilling Operational Experts Velan Capital, L.P. – ALL RIGHTS RESERVED 103

  104. Slide 104: Radiopharma: Challenging Supply Chain

    Radiopharma: Challenging Supply Chain Radiopharmaceutical manufacturing requires well-timed logistics given its ready-to-order / use requirements Radiopharmaceutical products have short shelf-lives, ranging from minutes to a few days A tightly integrated supply chain is required to turn customer ord

  105. Slide 105: Overview of Typical Manufacturing Suite

    Overview of Typical Manufacturing Suite The image on the right is an example of a radiopharmaceutical suite Production capacity is driven by technical yield Speed and efficiency at which product can be PAGE CONTAINS NOMINEE PLAN / ACTIONS made (each minute that passes, product is lost) Need to overs

  106. Slide 106: Manufacturing Process Similarities

    Manufacturing Process Similarities LUTATHERA (AAA) MARKET UPTAKE AND SUPPLY CHAIN IN ITS LAUNCH YEAR Currently sole AZEDRA SUPPLY CHAIN source with an upcoming potential shutdown A similar supply chain was established by Nominees Dr. Ber and Mr. Mäusli Source: Company filings, press releases and htt

  107. Slide 107: LUTATHERA's Manufacturing Process

    LUTATHERA’s Manufacturing Process Source: AAA corporate presentation. Velan Capital, L.P. – ALL RIGHTS RESERVED 107

  108. Slide 108: Putting in Place Operational Experts

    Putting in Place Operational Experts Dr. Gérard Ber co-founded and served as the Chief Operating Officer of Advanced Accelerator Applications S.A. (“AAA”) (formerly NASDAQ: AAAP), a pioneering radiopharmaceutical company that develops, produces and commercializes diagnostic and therapeutic products

  109. Slide 109: AAA's Approach to Manufacturing

    AAA’s Approach to Manufacturing In February 2017, nearly one year prior to LUTATHERA’s FDA approval, Nominees Dr. Ber and Mr. Mäusli, two of the three leading executives at AAA, published the below information in an investor deck Illustrates the team’s keen focus on manufacturing and commercial reac

  110. Slide 110: Future Clinical & Product Development Success

    100-Day Plan Future Clinical & Product Development Success Velan Capital, L.P. – ALL RIGHTS RESERVED 110

  111. Slide 111: 1095 Clinical Trial Held Hostage

    1095 Clinical Trial Held Hostage The Company uses CPDC as the supplier for 1095’s clinical trials In August 2018, CPDC was placed under an import ban by the FDA which meant it could not ship product into the United States We suspect that CPDC’s import ban is the reason why the 1095 Phase 2b clinical

  112. Slide 112: AZEDRA Basket Trial: Pipeline in a Product

    AZEDRA Basket Trial: Pipeline in a Product The full value of AZEDRA lies in expanding its treating indications beyond pheo and para The Company will provide further information on the basket trial later this year (nearly 18 months after its initial approval) but needs to move quickly given the marke

  113. Slide 113: Minimal Stockholder Communication

    Minimal Stockholder Communication To-date, the Company has disclosed minimal information regarding AZEDRA’s basket trial The images below capture the public information provided by the Company related to AZEDRA’s basket trial While the Company has “alignment” with the FDA, it does not state the tria

  114. Slide 114: Establishing Prudent Expense & Dilution Management

    100-Day Plan Establishing Prudent Expense & Dilution Management Velan Capital, L.P. – ALL RIGHTS RESERVED 114

  115. Slide 115: Approach to Expense Management

    Approach to Expense Management Comparing Progenics to other companies run by our Nominees illustrates the difference in G&A per employee (Progenics at ~$435k vs. ~€160k for AAA and ~$179k for Aptalis) and burn relative to net sales and cash balance Our Nominees would step in and control expenses to

  116. Slide 116: Addressing Potential Financing Need

    Addressing Potential Financing Need In addition to right-sizing the Company’s expenses, we believe strong non- dilutive financing alternatives are available to Progenics Monetization of RELISTOR royalties PAGE CONTAINS NOMINEE PLAN / ACTIONS Product- and project-based financing lenders We have a str

  117. Slide 117: Non-Dilutive Financing: RELISTOR Royalty

    Non-Dilutive Financing: RELISTOR Royalty On November 4, 2016, Progenics entered into a loan agreement (the “Royalty-Backed Loan”) with a fund managed by HealthCare Royalty Partners III, L.P. (“HCRP”) pursuant to which HCRP agreed to make term loans in an aggregate principal amount of up to $100 mill

  118. Slide 118: Viability of Side Projects: AI

    Viability of Side Projects: AI Our Nominees intend to validate the viability of Progenics’ artificial intelligence program Initially, the suggestion is to shut down this program PAGE CONTAINS NOMINEE PLAN / ACTIONS While Progenics has stated this program is “expected to break even in 2019” this year

  119. Slide 119: Proven Financial Ability in Radiopharma

    Proven Financial Ability in Radiopharma Nominees Dr. Ber and Mr. Mäusli were two of three key executives building AAA until its acquisition by Novartis for $3.9 billion. During their tenure, AAA accomplished multiple milestones: Registered 8 diagnostic drugs and one therapeutic drug Registered first

  120. Slide 120: Holding Management Accountable & Aligning Incentives with Stockholders

    100-Day Plan Holding Management Accountable & Aligning Incentives with Stockholders Velan Capital, L.P. – ALL RIGHTS RESERVED 120

  121. Slide 121: Aligning Objectives With Stockholders

    Aligning Objectives With Stockholders On August 8, 2019, the Company announced governance enhancements, including stock ownership guidelines for non-employee directors and executive officers Provides for each non-employee director and executive officer to achieve and maintain an equity interest in t

  122. Slide 122: Removing Flawed Cash Balance Goal

    Removing Flawed Cash Balance Goal In 2018, the Company established a year-end cash balance goal to measure management’s performance We believe setting a cash balance target incentivizes shareholder dilution and deprioritizes growth investments This directly contradicts stockholder goals as the cash

  123. Slide 123: Correcting Management Incentives

    Correcting Management Incentives Currently Progenics’ compensation program includes Equity awards which lack performance vesting conditions Annual incentive awards based on performance metrics with the payouts determined by a subjective assessment instead of objective goals Our Nominees would instil

  124. Slide 124: Ensure Proper Alignment of Director Pay

    Ensure Proper Alignment of Director Pay For 2018, the median of director pay at Progenics was $237,000, excluding then Chairman Crowley, who received more than $452,000 in 2018 According to an ISS Board Practices Study in 2017, the median compensation for directors at Small Cap companies in the Phar

  125. Slide 125: Management & Culture: Need for New Life at Progenics

    100-Day Plan Management & Culture: Need for New Life at Progenics Velan Capital, L.P. – ALL RIGHTS RESERVED 125

  126. Slide 126: Need for Interim CEO During Transition

    Need for Interim CEO During Transition Nominee David Mims will serve as interim CEO during transition period Mr. Mims is well equipped to manage Progenics Mr. Mims brings almost 30 years of experience in the specialty pharmaceuticals industry Considerable management and commercial operations experie

  127. Slide 127: Working with New Full-Time CEO

    Working with New Full-Time CEO Once a new CEO is identified it will be important for the Board to assist with the transition Ensure close working relationship with other Company executives, Board members and CEO All Nominees to provide candid insight to new CEO on issues and upsides at Progenics PAG

  128. Slide 128: Cultivate The Right Culture

    Cultivate The Right Culture As an oncology company with the objective to “find, fight and follow cancer”, Progenics needs a much-improved culture in order to achieve its full potential Current culture is plagued by missed objectives and neglected assets PAGE CONTAINS NOMINEE PLAN / ACTIONS Multiple

  129. Slide 129: Establishing an Employee Hotline

    Establishing an Employee Hotline There are multiple potentially concerning issues regarding questionable decisions made under the direction of CEO Mark Baker Not disclosing CPDC’s import ban PAGE CONTAINS NOMINEE PLAN / ACTIONS Raising $75 million in capital a few days after CPDC’s import ban was ef

  130. Slide 130: 100-Day Plan Additional Information

    100-Day Plan Additional Information Velan Capital, L.P. – ALL RIGHTS RESERVED 130

  131. Slide 131: Plan Timing: Management & Governance

    Plan Timing: Management & Governance PAGE CONTAINS NOMINEE PLAN / ACTIONS Note: Represents our Nominees’ views, analysis and research as of the date of this presentation. If elected, this plan and timeline may change based on new learnings in the boardroom. Velan Capital, L.P. – ALL RIGHTS RESERVED

  132. Slide 132: Plan Timing: Commercial

    Plan Timing: Commercial PAGE CONTAINS NOMINEE PLAN / ACTIONS Note: Represents our Nominees’ views, analysis and research as of the date of this presentation. If elected, this plan and timeline may change based on new learnings in the boardroom. Velan Capital, L.P. – ALL RIGHTS RESERVED 132

  133. Slide 133: Plan Timing: Operations & Supply

    Plan Timing: Operations & Supply PAGE CONTAINS NOMINEE PLAN / ACTIONS Note: Represents our Nominees’ views, analysis and research as of the date of this presentation. If elected, this plan and timeline may change based on new learnings in the boardroom. Velan Capital, L.P. – ALL RIGHTS RESERVED 133

  134. Slide 134: Plan Timing: Clinical Development

    Plan Timing: Clinical Development PAGE CONTAINS NOMINEE PLAN / ACTIONS Note: Represents our Nominees’ views, analysis and research as of the date of this presentation. If elected, this plan and timeline may change based on new learnings in the boardroom. Velan Capital, L.P. – ALL RIGHTS RESERVED 134

  135. Slide 135: Plan Timing: Financials & Financing

    Plan Timing: Financials & Financing PAGE CONTAINS NOMINEE PLAN / ACTIONS Our Nominees would also evaluate the current Lantheus offer as well as any improved / superior offers Note: Represents our Nominees’ views, analysis and research as of the date of this presentation. If elected, this plan and ti

  136. Slide 136: Impact of a Change in Control

    Impact of a Change in Control The Company’s revocation statement notes a change in control would impact the items below “The removal and replacement of the Board will constitute a change in control under the Loan Agreement. MNTX Royalties Sub LLC is a subsidiary of the Company. The Board will consid

  137. Slide 137: Velan's View of Progenics Value

    Velan’s View of Progenics’ Value Velan Capital, L.P. – ALL RIGHTS RESERVED 137

  138. Slide 138: Potential Value Tied to Proper Leadership

    Potential Value Tied to Proper Leadership Velan believes that Progenics has incredible upside under the leadership of a Board and CEO with the proper skillsets Successful pharmaceutical and radiopharmaceutical commercialization and supply chain expertise, investor relations and shareholder engagemen

  139. Slide 139: Progenics Stand-Alone Potential Value

    Progenics’ Stand-Alone Potential Value Includes 50% of NOLs prior to 2018; includes D&A and $65 million in CapEx Represents estimate as of YE2019 ($25mm quarterly cash burn, RELISTOR milestone payment and debt paydown) Unaffected Price: $4.95 Source: SEC filings. Note: Assumes 12% discount rate and

  140. Slide 140: Base Business: RELISTOR & AZEDRA

    Base Business: RELISTOR & AZEDRA RELISTOR, currently marketed by Bausch Health, VELAN’S PERSPECTIVE ON VALUE (11-13% DISCOUNT RATE) generates ~$100 million in annual sales currently Unaffected 15-19% royalties payable to Progenics Price: $4.95 Net sales milestone payments range from $10-75 million a

  141. Slide 141: Pipeline Opportunities: Therapeutics

    Pipeline Opportunities: Therapeutics AZEDRA label expansion VELAN’S PERSPECTIVE ON VALUE (11-13% DISCOUNT RATE) Assumes market is 3x size of existing indications to Unaffected account for both larger patient population and Price: $4.95 different dosing (could have material upside) As an example, pat

  142. Slide 142: Pipeline Opportunities: PyL Diagnostic

    Pipeline Opportunities: PyL Diagnostic PyL represents a significant opportunity where Progenics has the front-runner that is desperately needed in the marketplace Completed Phase 3 enrollment in August 2019 Top-line results expected in Q4 2019 with NDA submission in 2H 2020 Velan assumptions 2022 co

  143. Slide 143: Pipeline Opportunities: DCF Sensitivities

    Pipeline Opportunities: DCF Sensitivities Value Impact Value Impact Product Sensitivity at 11% Discount Rate at 13% Discount Rate 100% Probability of Success +$1.25 per share +$1.05 per share (75% Currently) Label 5x Market Size of New Indications Expansion +$2.80 per share +$2.45 per share vs. Pheo

  144. Slide 144: Additional Comments for Consideration

    Additional Comments for Consideration Operating expenses SG&A reduced by approximately one-third to $22 million in 2020 Additional savings could be available, but this is not a “buyout scenario” model SG&A increased as additional indications / products progress in the clinic Cumulative R&D expense o

  145. Slide 145: Comparing Our Model to Equity Research

    Comparing Our Model to Equity Research Product Velan’s Model Equity Research Perspectives Peak Net Sales BTIG forecasts royalties from RELISTOR of from Royalties of ~$38 million $79 million in 2023 Peak Net Sales BTIG forecasts AZEDRA 2020-2023 net sales of $110 million of $32-126 million Peak Proba

  146. Slide 146: Frame of Reference to Keep in Mind

    Frame of Reference to Keep in Mind 1095 comparable Endocyte was acquired for $2.1 billion with only one lead asset after its Phase 2 trial This alone would imply ~$23 per share Conversely, Progenics has multiple value-creating products in its pipeline Bracco / Blue Earth transaction for $475 million

  147. Slide 147: Conclusion

    Conclusion Velan Capital, L.P. – ALL RIGHTS RESERVED 147

  148. Slide 148: Now is the Time for Much Needed Change and Accountability at Progenics

    Now is the Time for Much Needed Change and Accountability at Progenics We believe Progenics’ value resides primarily with its RELISTOR royalties, approved drug AZEDRA, net cash, and pipeline However, it is critical to efficiently direct appropriate resources towards effective development, utilizatio

  149. Slide 149: Weighing Key Takeaways

    Weighing Key Takeaways Compelling Value Proposition Accountability, management oversight and stockholder alignment tip the scale in favor of enduring success Velan Capital, L.P. – ALL RIGHTS RESERVED 149

  150. Slide 150: Vote to Protect the Value of Your Investment on the GREEN Consent Card

    Vote to Protect the Value of Your Investment on the GREEN Consent Card TODAY CONSENT for the removal of CEO Baker, Dr. Scheinberg and Ms. Williams CONSENT for our five highly-qualified, fully-independent Nominees: Drs. Ber and Ende, Messrs. Mäusli and Mims, and Ms. MacDougall Velan Capital, L.P. – A

  151. Slide 151: Appendix

    Appendix Velan Capital, L.P. – ALL RIGHTS RESERVED 151

  152. Slide 152: Nominee Biographies

    Nominee Biographies Dr. Gérard Ber, age 61, co-founded and served as the Chief Operating Officer of Advanced Accelerator Applications S.A. (“AAA”) (formerly NASDAQ: AAAP), a pioneering radiopharmaceutical company that develops, produces and commercializes diagnostic and therapeutic products for seve

  153. Slide 153: Nominee Biographies (Contd)

    Nominee Biographies (Cont’d) Ann MacDougall, age 66, currently serves as the Chief Executive Officer of Dunollie Fund, a family impact investment fund that she co- founded in January 2018. She also currently serves as a Senior Advisor to Encore.org (“Encore”), a non-profit organization that promotes

  154. Slide 154: Nominee Biographies (Contd)

    Nominee Biographies (Cont’d) David W. Mims, age 56, has served as a member of the board of directors at each of Guideway Care, a healthcare company that provides technology-enabled care guidance, since May 2017 and SouthPoint Bank, a community banking institution, since August 2015. Previously, Mr.

  155. Slide 155: Background to Velan's Solicitation

    Background to Velan’s Solicitation After having followed the Company and its predecessors for years, Velan initiated its current investment in July 2018 and initially interacted with representatives of the Company during a telephonic conversation on November 29, 2018. Over the ensuing months, Velan

  156. Slide 156: Background to Velan's Solicitation (Contd)

    Background to Velan’s Solicitation (Cont’d) On March 27, 2019, the Participating Stockholders crossed the 5% ownership threshold, thereby triggering their obligation under the Securities Exchange Act of 1934 (the “Exchange Act”) to file a Schedule 13D within 10 calendar days. On April 4, 2019, Mr. C

  157. Slide 157: Background to Velan's Solicitation (Contd)

    Background to Velan’s Solicitation (Cont’d) On April 24, 2019, Messrs. Venkataraman, Heck, Sarpangal and Cooke held separate in-person meetings in New York City with Mr. Kishbauch and Ms. Williams to discuss their respective qualifications for serving on the Board. During Mr. Venkataraman’s meeting,

  158. Slide 158: Background to Velan's Solicitation (Contd)

    Background to Velan’s Solicitation (Cont’d) On May 22, 2019, Velan issued a press release with its first letter to stockholders and noting the launch of its campaign website – www.SavePGNX.com. On May 30, 2019, the Company filed its definitive proxy statement in connection with the 2019 Annual Meeti

  159. Slide 159: Background to Velan's Solicitation (Contd)

    Background to Velan’s Solicitation (Cont’d) On June 26, 2019, Progenics’ counsel delivered the Board’s counterproposal to Velan’s counsel, which included the retirement of one unidentified director by the 2020 Annual Meeting but offered the same terms for the appointment of new directors (two new di

  160. Slide 160: Background to Velan's Solicitation (Contd)

    Background to Velan’s Solicitation (Cont’d) On July 26, 2019, counsel for Velan reached out to counsel for Progenics in an effort to reach a constructive resolution with the Company following the certified vote and provided a revised proposal to the Board, which removed Velan’s prior request for non

  161. Slide 161: Background to Velan's Solicitation (Contd)

    Background to Velan’s Solicitation (Cont’d) On September 11, 2019, Progenics’ counsel delivered the Board’s response to Velan’s counsel, which included the following: (i) expiration of the standstill through the 2020 Annual Meeting; (ii) the addition of three new directors for a Board size of eight

  162. Slide 162: Background to Velan's Solicitation (Contd)

    Background to Velan’s Solicitation (Cont’d) Also on October 2, 2019, the Participating Stockholders filed Amendment No. 2 to its preliminary Consent Statement. On October 4, 2019, the Company filed Amendment No. 1 to its preliminary consent revocation statement. On October 4, 2019, Velan and certain

Progenics Pharmaceuticals — Proxy Contest (October 2019) on 6ix